Is Paxlovid FDA Approved for COVID-19 Treatment?

Paxlovid is fully FDA-approved for the treatment of mild-to-moderate COVID-19 in adults at high risk of progressing to severe illness, hospitalization, or death. The drug first entered use under an Emergency Use Authorization in late 2021 and received traditional approval in May 2023. That distinction matters more than it might seem, because the path from emergency authorization to full approval involved a large clinical trial, extensive real-world data, and some regulatory nuances that affect who can get the drug today.

From Emergency Authorization to Full Approval

The FDA issued an Emergency Use Authorization for Paxlovid on December 22, 2021, making it the first oral antiviral authorized for at-home treatment of COVID-19. At that point, data from Pfizer’s pivotal trial was strong enough to justify emergency access, but a traditional New Drug Application had not yet been reviewed. On May 25, 2023, the FDA granted full approval for adults who are at high risk of severe COVID-19. The European Union had granted its own authorization earlier, on January 28, 2022.

Adolescents aged 12 to 17 who weigh at least 40 kilograms remained covered under the EUA for a time, with the EUA revised in November 2023 to align labeling. By March 2024, the FDA announced that Paxlovid was no longer authorized for emergency use in any population, meaning its availability now rests entirely on the standard approval for adults.

The approval is specifically for people whose COVID-19 is mild to moderate but who face elevated risk of getting sicker. It is not approved for people already hospitalized with severe disease, and it is not approved as a preventive measure before or after exposure.

How Paxlovid Works

Paxlovid is actually two drugs packaged together: nirmatrelvir and ritonavir. Nirmatrelvir is the active antiviral. It blocks an enzyme the virus needs to replicate, called the main protease. Without that enzyme functioning, the virus cannot assemble the proteins it needs to make copies of itself.

Ritonavir does not fight the virus directly. Instead, it slows your body’s breakdown of nirmatrelvir by inhibiting a liver enzyme called CYP3A4. This keeps nirmatrelvir circulating in your bloodstream at effective levels for longer. Ritonavir has been used for decades as a booster in HIV treatment for the same reason.

This two-drug design is clever but comes with a trade-off. Because ritonavir is a powerful enzyme inhibitor, it interferes with how your body processes dozens of other medications. That pharmacological baggage is one of the biggest practical challenges with prescribing Paxlovid, and it is the reason the drug is not suitable for everyone.

The Trial That Earned Approval

The clinical trial that underpinned both the EUA and eventual full approval, known as EPIC-HR, enrolled unvaccinated adults at high risk of severe COVID-19. Among patients who started treatment within three days of symptom onset, fewer than 1% in the Paxlovid group were hospitalized or died by day 28, compared to about 7% in the placebo group. That translated to a relative risk reduction of roughly 89%. All 13 deaths in the trial occurred in the placebo group; none occurred among those who received Paxlovid.¹

Those numbers came from a population that had not been vaccinated, which is worth keeping in mind. By the time Paxlovid reached full approval, most of the world had some immunity from vaccination or prior infection. The question became whether the drug still made a meaningful difference in a partially immune population.

Real-World Performance After Vaccination

Several large studies have tried to answer that question, and the picture is reassuring if a bit less dramatic than the original trial. A large analysis using U.S. electronic health records found that both vaccinated and unvaccinated patients saw similar absolute reductions in hospitalization risk with Paxlovid. Vaccinated patients had a larger relative risk reduction, because their baseline risk of being hospitalized was already lower to begin with.²

In South Korea, a study of long-term care facility residents during an Omicron wave found that those who received Paxlovid had about half the rate of severe illness compared to untreated residents. Among residents who had received three vaccine doses, the rate of severe cases was about 71% lower and mortality was about 65% lower than in unvaccinated residents.³

A separate Korean study looking at the Omicron BA.5 variant found that Paxlovid treatment in patients aged 60 and older was associated with a 46% reduction in the risk of severe or critical illness or death, regardless of vaccination status.⁴

The consistent finding across these studies is that Paxlovid still reduces hospitalizations and deaths in the real world, even in populations with high vaccination rates. The benefit is most pronounced in older adults and those with multiple health conditions.

Why Starting Early Matters

Paxlovid is meant to be started within five days of symptom onset, and the earlier the better. The EPIC-HR trial data showed the strongest results when treatment began within three days. A retrospective study in elderly patients found that those who started Paxlovid within five days of symptoms had significantly shorter hospital stays, cleared the virus faster, and were far less likely to develop severe illness compared to those who started later.⁵

This creates a practical bottleneck. You need to test positive, get a prescription, and start the medication quickly. If you wait to see whether your symptoms get worse before seeking treatment, you may miss the window where Paxlovid does the most good. For people at high risk, the advice from most guidelines is to get tested promptly and talk to a doctor as soon as symptoms appear.

The Drug Interaction Problem

The ritonavir component is the source of Paxlovid’s most significant limitation. Because it powerfully inhibits CYP3A4, ritonavir can dramatically increase blood levels of many commonly prescribed medications. This is not a minor pharmacological footnote; it affects statins, certain blood thinners, some heart rhythm drugs, immunosuppressants, and many cancer treatments, among others.

For people on complex medication regimens, the interaction risk can be serious enough to make Paxlovid a poor choice. The French Society of Pharmacology and Therapeutics published guidelines specifically to help physicians navigate these interactions, reflecting how widespread the concern is in clinical practice.⁶

In some cases, a patient’s other medications can be temporarily paused or dose-adjusted for the five-day Paxlovid course. Research on cancer patients taking certain targeted therapies has explored reducing drug doses during the Paxlovid treatment window to maintain similar drug exposure while avoiding toxicity.⁷ But this requires careful coordination with a pharmacist or specialist, and for some drugs, even a brief interruption is risky.

A study of cancer patients compared Paxlovid directly to molnupiravir, the other oral antiviral available for COVID-19. Disease progression rates were similar between the two drugs, but patients on Paxlovid were significantly more likely to experience drug interactions or adverse events, with 30% encountering problems compared to none in the molnupiravir group.⁸ That does not mean molnupiravir is better in general, but it highlights that for patients on many other drugs, Paxlovid’s interaction profile is a genuine barrier.

Side Effects and “Paxlovid Mouth”

The most talked-about side effect is dysgeusia, an altered taste that patients have nicknamed “Paxlovid mouth.” It is a persistent metallic or bitter taste that lingers throughout the five-day treatment course. Research suggests this is caused by nirmatrelvir activating a specific bitter taste receptor.⁹ It is unpleasant but harmless, and it resolves once treatment ends.

Beyond the taste issue, diarrhea, nausea, and headache are common. A real-world study of outpatients found that intolerable side effects were the primary reason people stopped taking Paxlovid before finishing the course, accounting for about 70% of early discontinuations. Diarrhea and the bitter taste were the top complaints.¹⁰ Stopping early is a problem because incomplete courses may reduce effectiveness and could theoretically contribute to resistance.

The Rebound Question

Some people who take Paxlovid experience a return of symptoms or a positive test result after initially improving, a phenomenon often called “Paxlovid rebound.” Early on, this attracted significant media attention and created hesitancy around the drug. A prospective study tracking both Paxlovid-treated and untreated patients found that viral rebound occurred in about 14% of the Paxlovid group compared to about 9% of untreated participants. Symptom rebound was more pronounced: roughly 19% of Paxlovid-treated patients reported it versus 7% of untreated patients.¹¹

What is worth noting is that rebound happens in untreated COVID-19 too, just less frequently. Rebound episodes are generally mild and do not appear to lead to worse overall outcomes. The leading theory is that the five-day Paxlovid course suppresses viral replication enough for symptoms to resolve, but in some people the immune system has not yet fully cleared the virus by the time the drug wears off. A second wave of replication then produces a brief return of symptoms. This was not generally associated with differences in age, sex, or pre-existing conditions.

Does Paxlovid Reduce Long COVID Risk?

Whether Paxlovid can prevent long COVID has been one of the most debated questions since the drug’s authorization. The evidence so far is mixed and somewhat underwhelming. A large study using electronic health records from the N3C and RECOVER consortia found that Paxlovid treatment during acute COVID-19 did not significantly reduce overall long COVID incidence. However, it did show small protective effects against cognitive symptoms and fatigue. Among patients aged 65 and older, there was a modest reduction in overall long COVID risk, though the absolute benefit was small, with a number needed to treat of 233.¹²

A separate analysis found that Paxlovid reduced the risk of gastrointestinal long COVID symptoms by about 37% but was associated with a roughly doubled risk of eye and ear symptoms like tinnitus or blurred vision. Among non-hospitalized patients aged 60 to 75, there was a modest overall reduction in long COVID risk, but no significant effect was seen in other age groups.¹³

The honest takeaway is that Paxlovid was designed to prevent hospitalization and death, and it does that well. Its effect on long COVID appears to be limited and varies by organ system and age group. For now, long COVID prevention is not a strong reason to take or prescribe the drug on its own.

How Paxlovid Compares to Other Antivirals

Paxlovid is not the only oral antiviral option. Molnupiravir, sold as Lagevrio, works through a different mechanism: it introduces errors into the virus’s genetic code during replication, rather than blocking the protease enzyme. Early clinical trials suggested Paxlovid was more effective, but more recent real-world data in older adults has indicated comparable potency between the two drugs.¹⁴ Molnupiravir’s advantage is its much cleaner drug-interaction profile, which makes it a practical alternative for patients on medications that clash with ritonavir.

Remdesivir, an intravenous antiviral, remains an option for patients who cannot take oral medications or for whom both oral antivirals are unsuitable. A comparison of hospitalized patients treated with remdesivir versus Paxlovid found that Paxlovid-treated patients had lower mortality and were discharged faster, but the remdesivir group tended to include sicker patients who needed oxygen support, making a direct comparison difficult.¹⁵ In practice, the choice often comes down to whether the patient can take pills and whether their other medications allow it.

The Resistance Question

Any antiviral drug raises the question of whether the virus will eventually develop resistance. For Paxlovid, laboratory studies have identified mutations in the virus’s main protease that could reduce nirmatrelvir’s effectiveness. One study catalogued 100 naturally occurring mutations at the nirmatrelvir binding site and found that 20 of them maintained normal enzyme function while conferring meaningful resistance to the drug.¹⁶

Importantly, some of these resistant variants appear to have existed before Paxlovid was even introduced, meaning they did not arise because of drug pressure. Phylogenetic analysis has shown that several resistance-conferring mutations pre-date clinical use and are capable of spreading.¹⁷ In laboratory experiments, researchers have also generated viral variants with combinations of mutations that produced more than a 20-fold increase in the concentration of drug needed to block the virus.¹⁸

So far, clinically significant resistance has not been a widespread problem, but these findings underscore why researchers are pushing for the development of additional antivirals with different mechanisms of action. Relying on a single protease inhibitor over the long term carries inherent risk, and combination therapies targeting multiple viral proteins simultaneously may eventually become the standard approach, much as they did for HIV.

Public Awareness and Hesitancy

Despite being available for several years, Paxlovid is not as widely recognized as you might expect. A community survey in Singapore found that only about half of respondents were aware of the drug. Once given basic information about it, three-quarters said they would be willing to take it if prescribed, but fewer than 40% said they would proactively ask their doctor about it. The most common reasons for reluctance were concerns about side effects, cost, and the perception that COVID-19 is mild enough not to require treatment.¹⁹

That last point is a real tension in prescribing: the people who benefit most from Paxlovid are those at high risk of severe outcomes, but many of those same people now view COVID-19 as a minor illness because they have been vaccinated or have had mild prior infections. The drug’s side effects, its drug-interaction baggage, and lingering confusion about the rebound phenomenon all add friction. For physicians, the challenge is communicating that being vaccinated does not eliminate the risk of a bad outcome for everyone, particularly for older adults and people with multiple chronic conditions.